News headlines about Loxo Oncology (NASDAQ:LOXO) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Loxo Oncology earned a news impact score of 0.12 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 44.5945527645235 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Loxo Oncology (NASDAQ LOXO) opened at $85.56 on Tuesday. Loxo Oncology has a 1-year low of $34.50 and a 1-year high of $95.92. The company has a market cap of $2,553.67, a price-to-earnings ratio of -14.68 and a beta of 2.54.
A number of equities analysts have commented on the stock. Cowen reiterated a “buy” rating on shares of Loxo Oncology in a report on Thursday, September 28th. BTIG Research reiterated a “buy” rating and issued a $102.00 price objective (up previously from $75.00) on shares of Loxo Oncology in a report on Friday, September 29th. Morgan Stanley reiterated an “overweight” rating and issued a $103.00 price objective (up previously from $95.00) on shares of Loxo Oncology in a report on Friday, October 6th. Citigroup reiterated a “buy” rating and issued a $112.00 price objective (up previously from $86.00) on shares of Loxo Oncology in a report on Friday, October 20th. Finally, Ifs Securities upgraded shares of Loxo Oncology from an “outperform” rating to a “strong-buy” rating in a report on Tuesday, November 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $90.57.
In other news, Director Avi Z. Naider sold 5,000 shares of the business’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $90.00, for a total value of $450,000.00. Following the completion of the sale, the director now owns 144,118 shares of the company’s stock, valued at approximately $12,970,620. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Joshua H. Bilenker sold 7,500 shares of the business’s stock in a transaction dated Tuesday, October 31st. The stock was sold at an average price of $86.49, for a total transaction of $648,675.00. Following the completion of the sale, the chief executive officer now directly owns 196,207 shares of the company’s stock, valued at approximately $16,969,943.43. The disclosure for this sale can be found here. Insiders sold a total of 1,614,555 shares of company stock worth $124,567,942 in the last quarter. 27.80% of the stock is currently owned by company insiders.
Loxo Oncology Company Profile
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.